Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 11/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747610 | 1.00 | KLK5 (0.49) | KLK5BACE1CYP17A1CA1CA2 | |
| SCHEMBL13932832 | 0.90 | CA1 (0.54) | KLK5BACE1CYP17A1CA1CA2 | |
| SCHEMBL6747622 | 0.87 | KLK5 (0.52) | KLK5BACE1CYP17A1PSEN1PSEN2 | |
| SCHEMBL6747621 | 0.87 | KLK5 (0.52) | KLK5BACE1CYP17A1PSEN1PSEN2 | |
| SCHEMBL27796636 | 0.86 | KLK5 (0.63) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL27486450 | 0.86 | KLK5 (0.63) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL8486327 | 0.86 | KLK5 (0.63) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL27502332 | 0.86 | KLK5 (0.63) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL13538225 | 0.86 | KLK5 (0.51) | KLK5BACE1CYP17A1PSEN1PSEN2 | |
| Hydrochloric Acid SCHEMBL6753321 | 0.86 | KLK5 (0.51) | KLK5BACE1CYP17A1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699895-B2 | CYCLIZING THE TERT-BUTYL-THIOUREA DERIVATIVE TO FORM THE END PRODUCT | AVENTIS PHARMA S.A. (FR) | 2004-03-02 | — | — | US | disclosed |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-26 | — | — | US | disclosed |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-12 | — | — | US | disclosed |
| US-6451821-B1 | ADMINISTERING TO A PATIENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF 2-AMINOTHIAZOLINE DERIVATIVES FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH AN ABNORMAL PRODUCTION OF NITRIC OXIDE(NO) | AVENTIS PHARMA S.A. (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | AVENTIS PHARMA S.A. (FR) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | NOS2, NOS3, NOS1 | KLK5 4738/4885BACE1 3991/4885CYP17A1 789/4885 |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | NOS3, TH, CBR1 | KLK5 4617/4885BACE1 2900/4885CYP17A1 684/4885 |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | NOS2, NOS3, NOS1 | KLK5 4756/4885BACE1 4079/4885CYP17A1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.